Latest Advances in Lung Cancer Research

This article reviews strategies for managing treatment resistance in advanced EGFR-mutated lung cancer, focusing on personalization, parsimony, and partnership.

Tepotinib, the first FDA-approved treatment for MET-mutated lung cancer, improves tumor shrinkage and survival.

FDA approves osimertinib plus chemo as first-line treatment for EGFR-mutated lung cancer, improving survival.

Weill Cornell Medicine scientists create a mouse model to study lung cancer’s transformation into deadly SCLC.

Researchers who conducted a large study published in the journal Chest report that reproductive factors, such as early age at menopause and first childbirth, are associated with an increased risk of lung cancer.

Actress and comedian Kate Micucci, revealed last month that she had been diagnosed and treated for lung cancer despite having “never” smoked cigarettes. Micucci’s diagnosis came as a surprise to her followers, especially considering she is a non-smoker. However, lung cancer among non-smokers happens more often than most people realize.

Study finds lung cancer patients show distinct lung microbiome profiles versus benign diseases. Analyzing microbial features in bronchoalveolar lavage fluid could serve as minimally invasive biomarker for lung cancer detection, reducing need for biopsies.

Ohio State launched a mobile lung cancer screening unit to increase early detection statewide by bringing expert staff & the latest diagnostic tech to underserved areas. The goal is to boost screening rates.

Study finds NSCLC patients treated with low-dose radiation & immunotherapy had higher progression-free survival than with immunotherapy alone – combo extended PFS and bolstered immune response.

David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.

Changing the current lung cancer guidelines to a 2-year smoking duration cutoff vs a 20 pack-year cutoff would significantly improve the rate of cancer detection and reduce racial disparities with screenings.

LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints. Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression.